Jason Engel, MD
Urology · Washington, DCNPI 1285797605
Payments from drug & device makers
Across 245 payments — averaging $2987.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sumitomo Pharma America, Inc.$566K
- Davol Inc.$137K
- Ferring International Pharmascience Center US$14K
- Boston Scientific$10K
- Ferring Pharmaceuticals AS$3K
- Endo Pharmaceuticals Inc.$186
- plus $2K from 24 others
Across 3 payments — averaging $3082.16 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Spectrum Pharmaceuticals Inc.$8K
- Davol Inc.$2K
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sumitomo Pharma America, Inc. | 108 | $566,069 |
| Davol Inc. | 3 | $136,781 |
| Ferring International Pharmascience Center US | 2 | $14,330 |
| Boston Scientific | 60 | $9,830 |
| Ferring Pharmaceuticals AS | 1 | $3,210 |
| Endo Pharmaceuticals Inc. | 9 | $186 |
| Intuitive Surgical | 1 | $176 |
| Johnson & Johnson(3 entities) | 8 | $169 |
| Pfizer | 6 | $157 |
| Astellas Pharma US Inc | 8 | $149 |
| Axonics, Inc. | 8 | $137 |
| Dornier Medtech America, Inc | 1 | $135 |
| Urogen Pharma, Inc. | 4 | $105 |
| Telix Pharmaceuticals | 3 | $91 |
| Dendreon Pharmaceuticals LLC | 3 | $82 |
| Myovant Sciences Inc. | 4 | $74 |
| AbbVie | 3 | $51 |
| Olympus America Inc. | 1 | $33 |
| Urovant Sciences Inc | 1 | $24 |
| Therapeuticsmd, Inc. | 1 | $23 |
| Laborie Medical Technologies Corp. | 1 | $21 |
| Bayer | 1 | $20 |
| Foundation Medicine, Inc. | 1 | $19 |
| Gilead | 1 | $18 |
| Blue Earth Diagnostics | 1 | $17 |
| Hollister Incorporated | 1 | $17 |
| Zyla Life Sciences, Inc. | 1 | $16 |
| Convatec Inc. | 1 | $15 |
| Clovis Oncology, Inc. | 1 | $14 |
| Coloplast | 1 | $13 |
How this compares
$731,982 in reported general payments places this provider in the 95th percentile of 47 urology providers in District of Columbia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other urology in Washington
- Lambros StamatakisWashington$992K
- Inger RosnerWashington$65K
- Armine SmithWashington$58K
- Nathan ShawWashington$54K
- Patrick MufarrijWashington$31K
- Ryan HankinsWashington$29K
- Adam MetwalliWashington$27K
- Michael WhalenWashington$17K
- Pamela ColemanWashington$14K
- Leslie DeaneWashington$13K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.